Controlling Rotavirus-associated diarrhea: Could single-domain antibody fragments make the difference?;Hacia el control de la diarrea por rotavirus A: ¿podrían los nanoanticuerpos VHH marcar la diferencia?

Revista Argentina de Microbiologia

Volumn 47, Issue 4, 2015, Pages 368-379

  Maffey, Lucia ^a   Vega, Celina G ^a   Parreño, Viviana ^a   Garaicoechea, Lorena ^a  

^a INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

Author keywords

Nanobodies; Neonatal diarrhea; Rotavirus; Single domain antibody fragments; VHHs

Indexed keywords

ROTAVIRUS VACCINE; IMMUNOGLOBULIN FRAGMENT; PROBIOTIC AGENT;

ANTIGEN BINDING; ARTICLE; CHILDHOOD MORTALITY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; NONHUMAN; ROTAVIRUS INFECTION; VIRUS NEUTRALIZATION; ANIMAL; BANGLADESH; CHILD; MOUSE; NEWBORN; PIG; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS INFECTIONS; TRANSGENIC PLANT; VIROLOGY;

ANIMALS; ANIMALS, NEWBORN; BANGLADESH; CHILD; DIARRHEA; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; PLANTS, GENETICALLY MODIFIED; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROTAVIRUS INFECTIONS; SWINE;

EID: 84973620740     PISSN: 03257541     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ram.2015.09.005     Document Type: Article

References (72)

1. Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL, Nannemann DP, Meiler J, StewartPL, Crowe JE. Human Rotavirus VP6-specific antibodies mediateintracellular neutralization by binding to a quaternary structurein the transcriptional pore. PLOS ONE. 2013; 8: 12-4
2. Aladin F, Einerhand AWC, Bouma J, Bezemer S, Hermans P, Wolvers D, Bellamy K, Frenken LGJ, Gray J, Iturriza-GómaraM. In vitro neutralisation of rotavirus infection by two broadlyspecific recombinant monovalent llama-derived antibody frag-ments. PLoS ONE. 2012; 7: 329-49
3. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyam-bane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. Efficacy ofpentavalent rotavirus vaccine against severe rotavirus gastroen-teritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 376: 606-14
4. Azevedo MSP, Wen WZK, Gonzalez A, Saif L, Yousef A. Lactobacil-lus acidophilus and L. reuteri modulate cytokine responses ingnotobiotic pigs infected with human rotavirus. Benef Microbes. 2012; 3: 33-42
5. Babji S, Kang G. Rotavirus vaccination in developing countries. Curr Opin Virol. 2012; 2: 443-8
6. Bae E, Han M, Lee M, Kim D. In vitro inhibitory effectof some flavonoids on rotavirus infectivity. Biol Pharm Bull. 2000; 23: 1122-4
7. Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P. Experimental therapyof African trypanosomiasis with a nanobody-conjugated humantrypanolytic factor. Nat Med. 2006; 12: 580-4
8. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Shekhani MS, Siddiqi AQ. Role of a probiotic (Saccharomycesboulardii) in management and prevention of diarrhoea. WorldJ Gastroenterol. 2006; 12: 4557-60
9. Böhles N, Busch K, Hensel M. Vaccines against human diar-rheal pathogens: current status and perspectives. Hum VaccinesImmunother. 2014; 10: 1522-35.
10. Burns J, Krishnaney A, Vo P, Rouse R, Anderson L, Greenberg H. Analyses of homologous Rotavirus infection in the mouse model. Virology. 1995; 207: 143-53
11. Burns JW, Siadat-pajouh M, Krishnaney AA, Greenberg HB. Protective effect of Rotavirus VP6-specific IgA monoclonal anti-bodies that lack neutralizing activity. Science. 1996; 272: 104-7
12. Cartwright-Shamoon J, Dickson GR, Dodge J, Carr KE. Uptake ofyeast (Saccharomyces boulardii) in normal and rotavirus treatedintestine. Gut. 1996; 39: 204-9
13. Castello AA, Argüelles MH, Rota RP, Olthoff A, Jiang B, GlassRI, Gentsch JR, Glikmann G. Molecular epidemiology of groupA rotavirus diarrhea among children in Buenos Aires. Argentina, from 1999 to 2003 and emergence of the infrequent genotypeG12. J Clin Microbiol. 2006; 44: 2046-50
14. Ciarlet M, Schödel F. Development of a rotavirus vaccine: clin-ical safety, immunogenicity, and efficacy of the pentavalentrotavirus vaccine, RotaTeq. Vaccine. 2009; 27 Suppl. 6: G72-81
15. Corrêa NBO, Penna FJ, Lima FMLS, Nicoli JR, Filho LAP. Treat-ment of acute diarrhea with Saccharomyces boulardii in infants. J Pediatr Gastroenterol Nutr. 2011; 53: 497-501
16. Cortez-retamozo V, Backmann N, Senter PD, Wernery U, DeBaetselier P, Muyldermans S, Revets H. Efficient cancer therapywith a nanobody-based conjugate. Cancer Res. 2004; 64: 2853-7
17. De Genst E, Silence K, Decanniere K, Conrath K, Loris R, KinneJ, Muyldermans S, Wyns L. Molecular basis for the preferen-tial cleft recognition by dromedary heavy-chain antibodies. ProcNatl Acad Sci U S A. 2006; 103: 4586-91
18. Do Carmo GMI, Yen C, Cortes J, Siqueira AA, de Oliveira WK, Cortez-Escalante JJ, Lopman B, Flannery B, de Oliveira LH, Carmo EH, Patel M. Decline in diarrhea mortality and admis-sions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011; 8: e1001024.
19. Dumoulin M, Conrath K, Meirhaeghe AVAN, Meersman F, Here-mans K, Frenken LGJ, Muyldermans S, Wyns L, Matagne A. Single-domain antibody fragments with high conformationalstability. Protein Sci. 2002; 11: 500-15
20. Feng N, Yasukawa LL, Sen A, Greenberg HB. Permissive replica-tion of homologous murine Rotavirus in the mouse intestine isprimarily regulated by VP4 and NSP1. J Virol. 2013; 87: 8307-16
21. Forsman A, Beirnaert E, Aasa-Chapman MMI, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Ver-rips T, de Haard H, Weiss R. Llama antibody fragments withcross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol. 2008; 82: 12069-81
22. Frenken L, van der Linden R, Hermans P, Wil Bos J, Ruuls R, deGeus B, Verrips C. Isolation of antigen specific Llama V HH anti-body fragments and their high level secretion by Saccharomycescerevisiae. J Biotechnol. 2000; 78: 11-21
23. Garaicoechea L, Olichon A, Marcoppido G, Wigdorovitz A, Moz-govoj M, Saif L, Surrey T, Parre˜no V. Llama-derived single-chainantibody fragments directed to rotavirus VP6 protein possessbroad neutralizing activity in vitro and confer protection againstdiarrhea in mice. J Virol. 2008; 82: 9753-64
24. Gómez-Sebastián S, Nu˜nez MC, Garaicoechea L, Alvarado C, Mozgovoj M, Lasa R, Kahl A, Wigdorovitz A, Parre˜no V, Escrib-ano JM. Rotavirus A-specific single-domain antibodies producedin baculovirus-infected insect larvae are protective in vivo. BMCBiotechnol. 2012; 12: 59.
25. Grandy G, Medina M, Soria R, Terán CG, Araya M. Probioticsin the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probioticpreparations in Bolivian children. BMC Infect Dis. 2010; 10: 253.
26. Guerrant RL, DeBoer MD, Moore SR, Scharf RJ, Lima AA. The impoverished gut-a triple burden of diarrhoea, stunt-ing and chronic disease. Nat Rev Gastroenterol Hepatol. 2012; 10: 220-9
27. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E, Bendahman N, Hamers R. Naturally occur-ring antibodies devoid of light chains. Nature. 1993; 363: 446-8
28. Harmsen MM, De Haard HJ. Properties, production, and appli-cations of camelid single-domain antibody fragments. ApplMicrobiol Biotechnol. 2007; 77: 13-22
29. Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Iba˜nez LI, Vanlandschoot P, SchillemansJ, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, VanGucht S, de Haard HJ. Llama-derived single domain antibodiesto build multivalent, superpotent and broadened neutralizinganti-viral molecules. PLoS ONE. 2011; 6: e17665.
30. Jiang V, Jiang B, Tate J, Parashar UD, Patel MM. Performance ofrotavirus vaccines in developed and developing countries. HumVaccin. 2010; 6: 532-42
31. Kandasamy S, Chattha KS, Vlasova AN, Saif LJ. Prenatal vitaminA deficiency impairs adaptive immune responses to penta-valent rotavirus vaccine (RotaTeq®) in a neonatal gnotobioticpig model. Vaccine. 2014; 32: 816-24
32. Kim D, Song M, Bae E, Han M. Inhibitory effect ofherbal medicines on rotavirus infectivity. Biol Pharm Bull. 2000; 23: 356-8
33. Linhares AC, Stupka JA, Aruj PK, Bardach AE, Mazzoni A, BuendıJA, Lanzieri TM, Ortega-barria E, Colindres R. Burden and typingof rotavirus group A in Latin America and the Caribbean: system-atic review and meta-analysis. Rev Med Virol. 2011; 21: 89-109
34. Madhi S, Cunliffe N, Steele D, Witte D, Kirsten M, Louw C, NgwiraB, Victor J, Gillard P, Cheuvart BB, Han H, Neuzil K. Effect ofhuman rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010; 362: 289-98
35. Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. Thepig: a model for human infectious diseases. Trends Microbiol. 2012; 20: 50-7
36. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82: 775-97
37. Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, Nakanishi U, Matsumura A, Uozumi A, Hiroi T, Morita S, Tanaka K, Takaiwa F, Kiyono H. Rice-based mucosal vaccine as a globalstrategy for cold-chain-and needle-free vaccination. Proc NatlAcad Sci U S A. 2007; 104: 10986-91
38. Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarstrom L. Lactobacilli expressingvariable domain of llama heavy-chain antibody fragments (lac-tobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis. 2006; 194: 1580-8
39. Pant N, Marcotte H, Hermans P, Bezemer S, Frenken L, JohansenK. Lactobacilli producing bispecific llama-derived anti-rotavirusproteins in vivo for rotavirus-induced diarrhea. Future Micro-biol. 2011; 6: 583-93
40. Patel N, Hertel P, Estes M, de la Morena M, Petru A, NoroskiL, Revell P, Hanson I, Paul M, Rosenblatt H, Abramson S. Vaccine-acquired Rotavirus in infants with severe combinedimmunodeficiency. N Engl J Med. 2010; 362: 314-9
41. Preidis GA, Saulnier DM, Blutt SE, Mistretta T-A, Riehle KP, MajorAM, Venable SF, Barrish JP, Finegold MJ, Petrosino JF, GuerrantRL, Conner ME, Versalovic J. Host response to probiotics deter-mined by nutritional status of rotavirus-infected neonatal mice. J Pediatr Gastroenterol Nutr. 2012; 55: 299-307
42. Rossignol JF, Abu-Zekry M, Hussein A, Santoro MG. Effectof nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial. Lancet. 2006; 368: 124-9
43. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, BreuerT, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cer-vantes Y, Linhares AC, López P, Macías-Parra M, Ortega-BarríaE, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nu˜nez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-LlorensX, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine againstsevere rotavirus gastroenteritis. N Engl J Med. 2006; 354: 11-22
44. Salamone D, Bara˜nao L, Santos C, Bussmann L, Artuso J, Werning C, Prync A, Carbonetto C, Dabsys S, Munar C, Salaberry R, Berra G, Berra I, Fernández N, Papouchado M, Foti M, JudewiczN, Mujica I, Mu˜noz L, Alvarez SF, González E, Zimmermann J, Criscuolo M, Melo C. High level expression of bioactive recombi-nant human growth hormone in the milk of a cloned transgeniccow. J Biotechnol. 2006; 124: 469-72
45. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E, GutiérrezM. Racecadotril in the treatment of acute watery diarrhea inchildren. N Engl J Med. 2000; 343: 463-7
46. Santos N, Hoshino Y. Global distribution of rotavirusserotypes/genotypes and its implication for the develop-ment and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005; 15: 29-56
47. Sarker SA, Casswall TH, Juneja LR, Hoq E, Hossain I, FuchsGJ, Hammarström L. Randomized, placebo-controlled, clinicaltrial of hyperimmunized chicken egg yolk immunoglobulin inchildren with rotavirus diarrhea. J Pediatr Gastroenterol Nutr. 2001; 32: 19-25
48. Sarker SA, Jäkel M, Sultana S, Alam NH, Bardhan PK, ChistiMJ, Salam MA, Theis W, Hammarström L, Frenken LGJ. Anti-rotavirus protein reduces stool output in infants with diar-rhea: a randomized placebo-controlled trial. Gastroenterology. 2013; 145: 740-8
49. Sarker S, Casswall TH, Mahalanabis D, Alam N, Albert M, Brüssow H, Fuchs G, Hammerström L. Successful treatmentof rotavirus diarrhea in children with immunoglobulin fromimmunized bovine colostrum. Pediatr Infect Dis J. 1998; 17: 49-54
50. Sarker SA, Pant N, Juneja LR, Hammarström L. Successful treat-ment of Rotavirus-induced diarrhoea in suckling mice with eggyolk immunoglobulin. J Health Popul Nutr. 2007; 25: 465-8
51. Serruys B, Van Houtte F, Farhoudi-Moghadam A, Leroux-Roels G, Vanlandschoot P. Production, characterization andin vitro testing of HBcAg-specific VHH intrabodies. J Gen Virol. 2010; 91: 643-52
52. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, WynsL, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S. Efficient targeting of conserved cryptic epitopes of infectiousagents by single domain antibodies. African trypanosomes asparadigm. J Biol Chem. 2004; 279: 1256-61
53. Stoger E, Sack M, Perrin Y, Vaquero C, Torres E, Twyman RM, Christou P, Fischer R. Practical considerations for pharmaceuti-cal antibody production in different crop systems. Mol Breed. 2002; 9: 149-58
54. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, ForsmanQuigley A, Hulsik DL, Chen L, Weiss R, de Haard H, Verrips T. Llama antibody fragments recognizing various epitopes of theCD4 bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE. 2012; 7: e33298.
55. Szajewska H, Mrukowicz JZ. Probiotics in the treatmentand prevention of acute infectious diarrhea in infants andchildren: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr. 2001; 33: S17-24
56. Tate J, Burton AH, Boschi-Pinto C, Duncan Steele A, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associatedmortality in children younger than 5 years before theintroduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2008; 12: 136-41
57. Teran CG, Teran-Escalera CN, Villarroel P. Nitazoxanide vs. pro-biotics for the treatment of acute rotavirus diarrhea in children: a randomized, single-blind, controlled trial in Bolivian children. Int J Infect Dis. 2009; 13: 518-23
58. Tokuhara D, Álvarez B, Mejima M, Hiroiwa T, Takahashi Y, Kurokawa S, Kuroda M, Oyama M, Kozuka-hata H, Nochi T, Sagara H, Aladin F, Marcotte H, Frenken LGJ, Iturriza-gómaraM, Kiyono H, Hammarström L, Yuki Y. Rice-based oral antibodyfragment prophylaxis and therapy against rotavirus infection. JClin Invest. 2013; 123: 3829-38
59. Van Berkel PH, Welling MM, Geerts M, van Veen HA, Ravens-bergen B, Salaheddine M, Pauwels EK, Pieper F, Nuijens JH, Nibbering PH. Large scale production of recombinant humanlactoferrin in the milk of transgenic cows. Nat Biotechnol. 2002; 20: 484-7
60. Van der Vaart JM, Pant N, Wolvers D, Bezemer S, HermansPW, Bellamy K, Sarker SA, van der Logt CPE, Svensson L, Verrips CT, Hammarstrom L, van Klinken BJW. Reduction inmorbidity of rotavirus induced diarrhoea in mice by yeast pro-duced monovalent llama-derived antibody fragments. Vaccine. 2006; 24: 4130-7
61. Vega CG, Bok M, Vlasova AN, Chattha KS, Fernández FM, Wig-dorovitz A, Parre˜no VG, Saif LJ. IgY antibodies protect againsthuman Rotavirus induced diarrhea in the neonatal gnotobioticpiglet disease model. PLoS ONE. 2012; 7: e42788.
62. Vega CG, Bok M, Vlasova AN, Chattha KS, Gómez-SebastiánS, Nu˜nez C, Alvarado C, Lasa R, Escribano JM, GaraicoecheaLL, Fernandez F, Bok K, Wigdorovitz A, Saif LJ, Parre˜noV. Recombinant monovalent llama-derived antibody frag-ments (VHH) to rotavirus VP6 protect neonatal gnotobioticpiglets against human rotavirus-induced diarrhea. PLoS Pathog. 2013; 9: e1003334.
63. Vesikari T, Karvonen A, Puustinen L, Zeng S-Q, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 live attenuated humanrotavirus, vaccine in Finnish infants. Pediatr Infect Dis J. 2004; 23: 937-43
64. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shine-field HR, Christie CDC, Ylitalo S, Itzler RF, Coia ML, OnoratoMT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvnen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, BoslegoJW, Offit P, Heaton PM. Safety and efficacy of a pentavalenthuman-bovine (WC3) reassortant rotavirus vaccine. N Engl JMed. 2006; 354: 23-33
65. Vlasova AN, Chattha KS, Kandasamy S, Siegismund CS, Saif LJ. Prenatally acquired vitamin A deficiency alters innate immuneresponses to human rotavirus in a gnotobiotic pig model. JImmunol. 2013; 190: 4742-53
66. Ward LA, Rosen BIYL. Pathogenesis of an attenuated and a vir-ulent strain of group A human rotavirus in neonatal gnotobioticpigs. J Gen Virol. 1996; 77: 1431-41
67. Wei G, Meng W, Guo H, Pan W, Liu J, Peng T, Chen L, ChenC-Y. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS ONE. 2011; 6: e28309.
68. WHO-UNICEF, Johns Hopkins School of Public Health U. Implementing the New Recommendations on the ClinicalManagement of Diarrhoea Guidelines for Policy Makers andProgramme Managers. World Health Organization, Depart-ment of Child and Adolescent Health and Development, andUnited Nations Children's Fund, Programme Division. P 1-4; 2006.
69. Yuan L, Ward LA, Rosen BI, To TL, Saif LJ, Irol JV. Systemic andintestinal antibody-secreting cell responses and correlates ofprotective immunity to human Rotavirus in a gnotobiotic pigmodel of disease. J Virol. 1996; 70: 3075-83
70. Yuan L, Wen K, Wang H, Shepherd M, Li G, Yang X, Kocher J, Giri-Rachman E, Karyala S, Settlage R. Lactobacillus rhamnosusGG (LGG) enhances virus-specific effector T cell responses induced by human rotavirus vaccine in neonatal human gutmicrobiota associated gnotobiotic pigs (P6320). J Immunol. 2013; 190: 182.
71. Zaman K, Duc Anh D, Victor J, Shin S, Yunus M, Dallas M, PodderG, Thiem V, Phuong Mai L, Luby S, Tho L, Coia M, Lewis K, RiversS, Sack D, Schödel F, Duncan Steele A, Neuzil K, Ciarlet M. Effi-cacy of pentavalent rotavirus vaccine against severe rotavirusgastroenteritis in infants in developing countries in Asia: arandomised, double-blind, placebo-controlled trial. Lancet. 2010; 376: 615-23
72. Zhang Z, Xiang Y, Li N, Wang B, Ai H, Wang X, Huang L, Zheng Y. Protective effects of Lactobacillus rhamnosus GG against humanrotavirus-induced diarrhoea in a neonatal mouse model. PathogDis. 2013; 67: 184-91.